.png)
Total amount raised
$33M
Latest funding date
2026-03-12
Location
Waiv has raised $33 million in its inaugural financing round, backed by five investors including OTB Ventures, Alpha Intelligence Capital, Serena Data Ventures, Karista, and SistaFund.
What Is Waiv?
Waiv is a Paris-based AI precision testing company spun out of Owkin, the French-American biotech unicorn, where it previously operated as Owkin Dx. Founded and led by CEO Meriem Sefta and leveraging over a decade of Owkin's foundational medical AI research, Waiv develops clinical-grade, AI-powered precision tests for oncology. Its platform analyzes digital histopathology and multimodal clinical data to identify biomarkers, predict treatment response, and stratify patients in the clinic and in clinical trials. Key products include RlapsRisk® BC (breast cancer relapse risk profiling), MSIntuit® CRC (colorectal cancer MSI/dMMR detection), BRCAura® RUO (germline BRCA mutation detection), and Destra®, a digital pathology deployment platform that integrates with existing lab systems. Waiv collaborates with leading pharmaceutical companies, including MSD (since 2023 for MSIntuit), and works with world-class medical institutions globally.
How Much Funding Has Waiv Raised?
Waiv has raised a total of $33 million across one disclosed funding round. Below is a breakdown of Waiv's funding history:
- Series Unknown (Spin-Out Financing)
- Amount Raised: USD 33,000,000
- Date: March 12, 2026
- Lead Investors: OTB Ventures and Alpha Intelligence Capital
- Participating Investors: Serena Data Ventures, Karista, SistaFund
Total Amount Raised: USD 33,000,000.
Key Investors
- OTB Ventures
- Details: OTB Ventures is a pan-European deep tech venture capital fund founded in 2017 and based in Amsterdam, Netherlands. The firm focuses on DeepTech startups at the late Seed and Series A stages, with key verticals including Enterprise Automation & AI, Cybersecurity, and SpaceTech. OTB Ventures co-led Waiv's $33M spin-out financing in March 2026.
- Alpha Intelligence Capital (AIC)
- Details: Alpha Intelligence Capital is a global, entrepreneurs-led venture capital fund investing in AI-first companies worldwide, from Seed to Series B stages. The firm targets sectors including healthcare, fintech, and energy with a focus on deep AI/ML innovation. AIC co-led Waiv's $33M financing round in March 2026.
- Serena Data Ventures
- Details: Serena Data Ventures is an early-stage venture capital fund managed by Serena, a Paris-based VC firm founded in 2008 and one of Europe's first VC funds dedicated to AI and data-driven business models. Serena Data Ventures participated in Waiv's March 2026 financing round.
- Karista
- Details: Karista is a Paris-based early-stage European venture capital firm founded in 2001, investing across Health, DeepTech, and Digital from Seed to Series B+. With a portfolio of over 100 companies over nearly 25 years, Karista participated in Waiv's inaugural $33M financing round in March 2026.
- SistaFund
- Details: SistaFund is a Paris-based pan-European venture capital fund backing female founders and gender-balanced teams, founded in 2022. The fund invests in early-stage companies challenging the status quo. SistaFund participated in Waiv's March 2026 spin-out financing round.
What's Next for Waiv?
With $33 million in fresh funding, Waiv is focused on accelerating the global deployment of its AI precision testing platform. The company plans to expand its portfolio of clinical-grade multimodal tests, deepen pharmaceutical integrations, and broaden international market access for laboratories and clinicians worldwide. Building on its collaboration with MSD and its PortrAIt consortium dataset network, Waiv aims to make AI-powered precision testing the global standard in oncology care.
Use Clay to Get Funding Data
Sales professionals, leverage Clay's platform to access comprehensive fundraising data, including Waiv's latest round details and investor profiles. Sign up for free today.
